Wednesday, September 20, 2023 12:58:57 PM
What are you babbling about? Here is a link to clinical trial data for TWO phase 3 trials of Daxxify in aesthetics
https://pubmed.ncbi.nlm.nih.gov/31609882/
Here is a link to clinical trial data for TWO phase 3 trials of Daxxify in cervical dystonia
https://practicalneurology.com/news/daxxify-receives-fda-approval-to-treat-cervical-dystonia
Bbbbwwwaaaa hhhhaaaa, so we should trust an anonymous message board poster who doesn't seem to know much and who lies by saying there was only one phase 3 clinical trial and when called on it disregards data from multiple phase 3 clinical trials in both aesthetics and in cervical dystonia.
So nice of you to be concerned but your concerns are misplaced. I am only down about 30% with the recent drop. Yes you are an anonymous message board poster who is providing your opinion, which is fine and you are welcome to do it. What isn't fine is you making claims that cannot be substantiated about supposedly having real world data while either lying about the number of phase 3 clinical trials or disregarding the solid data from MULTIPLE phase 3 clinical trials. Add in that the fact you just arrived and that adds suspicion to your motives.
Yes Foley and his team have made numerous missteps and marketing failures do happen. We will see how the price cuts affects market share in aesthetics and see how the Daxxify roll-out in CD goes. Those will help determine the long-term success for RVNC investors, not the comments of an anonymous message board poster.
Recent RVNC News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 11:15:36 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/16/2024 09:01:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:06:45 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 09/05/2024 09:27:28 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 09/05/2024 08:45:25 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 08/13/2024 01:29:06 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 08/12/2024 09:18:26 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc. • PR Newswire (US) • 08/12/2024 07:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:20:58 PM
- Crown Laboratories and Revance Announce Entry Into Merger Agreement • PR Newswire (US) • 08/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:00:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:34:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:07:57 PM
- Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 08/08/2024 08:05:00 PM
- Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • Business Wire • 08/01/2024 08:05:00 PM
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/14/2024 08:05:00 PM
- Revance to Participate in Upcoming Investor Conferences • Business Wire • 05/28/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:33:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:08:10 PM
- Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 05/09/2024 08:06:00 PM
- Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia • Business Wire • 05/09/2024 08:05:00 PM
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 • Business Wire • 05/02/2024 08:05:00 PM
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting • Business Wire • 04/12/2024 12:00:00 PM
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/27/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:33:10 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM